Stocks · News reference
Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America.Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification from
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Warren calls Bank of America's $1.2 Billion AML penalty a slap on the wrist, urging tougher sanctions and a criminal probe as earnings fall.
The article ranks the four largest U.S. money-center banks. JPMorgan Chase is rated best for long-term consistency with industry-leading returns and premium valuation. Citigroup shows the most near-term upside potential following its successful turnaround strategy. Bank of America faces headwinds from low-yielding bond holdings but benefits from stable deposits. Wells Fargo, while solid, has already seen significant near-term gains and trades at full valuation.
Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV for an €8 million upfront payment plus up to $230 million in milestone payments and royalties. The transaction marks the near-completion of Lakefront's previously announced wind-down of cell therapy activities, allowing the company to focus on its T-cell engager pipeline while providing shareholders potential upside from Armed Cell's future progress.
Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics for €8 million upfront plus up to $230 million in milestone payments and royalties. The sale marks the substantial completion of Lakefront's previously announced wind-down of legacy cell therapy activities, allowing the company to focus on its newly established T-cell engager pipeline while shareholders retain potential upside from future progress.